These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31550267)

  • 1. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    Londoño MC; Riveiro-Barciela M; Ahumada A; Muñoz-Gómez R; Roget M; Devesa-Medina MJ; Serra MÁ; Navascués CA; Baliellas C; Aldamiz-Echevarría T; Gutiérrez ML; Polo-Lorduy B; Carmona I; Benlloch S; Bonet L; García-Samaniego J; Jiménez-Pérez M; Morán-Sánchez S; Castro Á; Delgado M; Gea-Rodríguez F; Martín-Granizo I; Montes ML; Morano L; Castaño MA; de Los Santos I; Laguno M; Losa JE; Montero-Alonso M; Rivero A; de Álvaro C; Manzanares A; Mallolas J; Barril G; González-Parra E; García-Buey L
    PLoS One; 2019; 14(9):e0221567. PubMed ID: 31550267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
    Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
    J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
    Sanai FM; Alghamdi AS; Afghani AA; Alswat K; AlZanbagi A; Alghamdi MN; AlMousa A; Aseeri M; Assiri AM; Babatin MA
    Liver Int; 2018 Aug; 38(8):1395-1401. PubMed ID: 29288514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
    J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    Manuel Sousa J; Vergara M; Pulido F; Sánchez Antolín G; Hijona L; Carnicer F; Rincón D; Salmerón J; Mateos-Muñoz B; Jou A; Polo-Lorduy B; Rubín Á; Escarda A; Aguilar P; Aldámiz-Echevarría T; García-Buey L; Carrión JA; Hernández-Guerra M; Chimeno-Hernández S; Espinosa N; Morillas RM; Andrade RJ; Delgado M; Gallego A; Magaz M; Moreno-Planas JM; Estébanez Á; Rico M; Menéndez F; Sampedro B; Morano L; Izquierdo S; Zozaya JM; Rodríguez M; Morán-Sánchez S; Lorente S; Martín-Granizo I; Von-Wichmann MÁ; Delgado M; Manzanares A
    PLoS One; 2019; 14(11):e0225061. PubMed ID: 31714950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.
    Fofiu C; Boeriu A; Coman F; Fofiu A; Panic N; Bulajic M; Dobru D
    Ann Hepatol; 2019; 18(1):137-143. PubMed ID: 31113582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
    Wu J; Huang P; Fan H; Tian T; Xia X; Fu Z; Wang Y; Ye X; Yue M; Zhang Y
    Virol J; 2019 Jan; 16(1):11. PubMed ID: 30654809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
    Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
    Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
    J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
    Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
    Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
    Tatar B; Köse Ş; Ergun NC; Turken M; Onlen Y; Yılmaz Y; Akhan S
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1470-1475. PubMed ID: 31994628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
    Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
    Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
    Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
    Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.